알츠하이머 치매 환자에서 치료 전 중증도에 따른 약물의 장기 치료 효과
The Long-Term Outcomes of Alzheimer’s Disease Patients Treated with Anti-Dementia Medications According to Baseline Dementia Severity
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives：To describe the differences in long-term outcomes in Alzheimer’s disease (AD) patients according to initial dementia severity. Methods：A retrospective chart review of AD patients from a dementia clinic at the University Hospital in Korea was conducted from April 2010 to March 2017. There were 168 patients enrolled, who were divided into three groups based on initial Clinical Dementing Rating (CDR). There were 55 in the very mild group (CDR=0.5 ; mean age 80.64±6.57), 93 in the mild group (CDR=1 ; mean age 80.57±7.28) and 20 in the moderate group (CDR=2 ; mean age 83.00±9.07). Participants were treated with donepezil±memantine. The observation period was 2.44±0.50 years. Cognitive function and severity of dementia were initially assessed by the Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Assessment Battery (CERAD-NP) and were annually assessed by Mini-Mental State Exam (MMSE), CDR and CDR-Sum of boxes (CDR-SB). Results：The annual decline rate of MMSE score was -0.82 and those of very mild, mild, moderate groups were -0.63, -0.80, -1.96 respectively, while the annual change in CDR-SB score was 0.98, very mild group 0.86, mild group 1.03, moderate group 1.26. Education level, male, initial CDR were found to be significant potential factors in the annual change in MMSE, while initial CDR was a significant potential factor in the annual change in CDR-SB. Conclusion：It is meaningful that we studied long-term outcomes of anti-dementia medications in real-world clinical setting. The higher the initial severity of AD, the higher the cognitive decline rate.
Abstract
Objectives：To describe the differences in long-term outcomes in Alzheimer’s disease (AD) patients according to initial dementia severity. Methods：A retrospective chart review of AD patients from a dementia clinic at the University Hospital in Korea was conducted from April 2010 to March 2017. There were 168 patients enrolled, who were divided into three groups based on initial Clinical Dementing Rating (CDR). There were 55 in the very mild group (CDR=0.5 ; mean age 80.64±6.57), 93 in the mild group (CDR=1 ; mean age 80.57±7.28) and 20 in the moderate group (CDR=2 ; mean age 83.00±9.07). Participants were treated with donepezil±memantine. The observation period was 2.44±0.50 years. Cognitive function and severity of dementia were initially assessed by the Consortium to Establish a Registry for Alzheimer’s Disease Neuropsychological Assessment Battery (CERAD-NP) and were annually assessed by Mini-Mental State Exam (MMSE), CDR and CDR-Sum of boxes (CDR-SB). Results：The annual decline rate of MMSE score was -0.82 and those of very mild, mild, moderate groups were -0.63, -0.80, -1.96 respectively, while the annual change in CDR-SB score was 0.98, very mild group 0.86, mild group 1.03, moderate group 1.26. Education level, male, initial CDR were found to be significant potential factors in the annual change in MMSE, while initial CDR was a significant potential factor in the annual change in CDR-SB. Conclusion：It is meaningful that we studied long-term outcomes of anti-dementia medications in real-world clinical setting. The higher the initial severity of AD, the higher the cognitive decline rate.
참고문헌 (24)
- Youn JC, "Epidemiology of dementia", Psychiatry Investigation, 2, pp.8~ (2005)
- Fratiglioni L, "Epidemiology of the dementia of old age" (2008), Oxford University press
- Reisberg B, "Memantine in moderate-to-severe Alzheimer’s disease", New Engl J Med, 348, pp.1333~1341 (2003)
- Rolinski M, "Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease", Cochrane Database Syst Rev, 2012, pp.CD006504~ (2012)
- Wang HF, "Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis", J Neurol Neurosurg Psychiatry, 86, pp.135~143 (2015)
- Stinton C, "Pharmacological management of lewy body dementia : a systematic review and meta-analysis", Am J Psychiatry, 172, pp.731~742 (2015)
- Orrego F, "The chemical nature of the main central excitatory transmitter : a critical appraisal based upon release studies and synaptic vesicle localization", Neuroscience, 56, pp.539~555 (1993)
- Danysz W, "Glycine and N-methyl-D-aspartate receptors : physiological significance and possible therapeutic applications", Pharmacol Rev, 50, pp.597~664 (1998)
- Birks J, "Cholinesterase inhibitors for Alzheimer’s disease", Cochrane Database Syst Rev, pp.CD005593~ (2006)
- Mohs RC, "A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients", Neurology, 57, pp.481~488 (2001)
- Lee JH, "Development of the Korean version of Consortium to Establish a Resistry for Alzheimer’s Disease Assessment Packet(CERAD-K) : clinical neuropsychological batteries", J Gerontol B Psychol Sci Soc Sci, 57, pp.47~53 (2002)
- Choi SH, "Estimating the validity of the Korean version of expanded Clinical Dementia Rating(CDR)Scale", J Korean Neurol Assoc, 19, pp.585~591 (2001)
- Han HR, "Feasibility and validity of dementia assessment by trained community health workers based on Clinical Dementia Rating", J Am Geriatr Soc, 61, pp.1141~1145 (2013)
- Yang YH, "Longitudinal neuropsychological outcome in Taiwanese Alzheimer’s disease patients treated with medication", Current Alzheimer Research, 15, pp.474~ (2018)
- Williams MM, "Progression of Alzheimer’s disease as measured by clinical dementia rating sum of boxes scores", Alzheimers Dement, pp.S39~S44 (2013)
- Storandt M, "Rates of progression in mild cognitive impairment and early Alzheimer’s disease", Neurology, 59, pp.1034~1041 (2002)
- Tariot PN, "Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : a randomized controlled trial", JAMA, 291, pp.317~324 (2004)
- Porsteinsson AP, "Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial", Curr Alzheimer Res, 5, pp.83~89 (2008)
- Helzner EP, "Contribution of vascular risk factors to the progression in Alzheimer disease", Arch Neurol, 66, pp.343~348 (2009)
- Craft S, "Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer’s disease", Neurology, 51, pp.149~153 (1998)
- Mielke MM, "Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer’s disease", J Alzheimer’s Dis, 26, pp.127~134 (2011)
- Martins CA, "APOE alleles predict the rate of cognitive decline in Alzheimer disease : a nonlinear model", Neurology, 65, pp.1888~1893 (2005)
- Koepsell TD, "Education, cognitive function, and severity of neuropathology in Alzheimer disease", Neurology, 70, pp.1732~1739 (2008)
- Sohn D, "Sex differences in cognitive decline in subjects with high likelihood of mild cognitive impairment due to Alzheimer’s disease", Sci Rep, 8, pp.1~8 (2018)